Plerixafor in combination with G-CSF has shown to significantly increase the number of peripheral CD34 + cells as compared to G-CSF alone when used upfront in multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL) patients undergoing ASCT (3). This evidence concerns the gene CSF3 and non-Hodgkin lymphoma.